Key result
Losartan accelerates diabetic wound closure and normalizes stromal responses in mice.
Why the study?
Tissue regeneration and wound healing are severely impaired in diabetes and associated with poor circulation and dysfunctional blood vessels, motivating investigation of angiotensin II inhibition effects.
p-value: p=<0.05
Hypothesis-generating for losartan in diabetic wounds; prospective human trials needed before clinical adoption.
Tissue regeneration and wound healing are severely impaired in diabetes and are associated with poor circulation and dysfunctional blood vessels. Angiotensin II inhibitors are anti-hypertensive drugs used in clinical practice to regulate blood pressure and could affect tissue remodeling. We hypothesize that blocking angiotensin II, using Losartan, could facilitate tissue regeneration in diabetic mice. To this end, we established an experimental model of wound healing in streptozotocin-induced diabetic mice. Our data demonstrated that Losartan accelerates wound repair and normalizes wound stromal responses, having a beneficial role in wounds of diabetic individuals. Our findings highlight a potential therapeutic use of Losartan in improving wound repair in diabetic conditions.
No takes yet. Share an insight, caveat, or question.
eKamber et al. (2015) studied Diabetes-impaired wound healing (n=55). Losartan vs. Vehicle/No treatment in diabetic mice was evaluated on Open wound width at 3 days and granulation tissue width at 7 days (p=<0.05). Daily administration of the angiotensin II inhibitor losartan significantly accelerated epidermal wound closure and normalized wound stromal responses in diabetic mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: